Data investigation
Is Compounded Tirzepatide Safe? What FDA Has Actually Reported
FDA has never reviewed compounded tirzepatide for safety, effectiveness or quality. That is a fact about regulatory review, not a finding of harm. This covers what the agency has reported, what separates a 503A pharmacy from a 503B facility, and what nobody can tell you.
Part of Safety and side effects, separated from the headlines
No one has the evidence to tell you compounded tirzepatide is safe, and no one has the evidence to tell you it is dangerous. The vial in your refrigerator has not been through FDA review, so the agency has never evaluated that preparation for safety, effectiveness or quality.[1] That is a fact about paperwork rather than a finding about harm. What FDA does have is a list of things that have gone wrong, and you should know every item on it before you decide.
What “not FDA-approved” does and does not tell you
Approval is a review of one specific product made one specific way. An approved tirzepatide injection carries a strength printed on a label the agency signed off on, made in a plant held to a standard the agency inspects against, with a safety profile assembled from trials the agency read. A compounded vial has none of that behind it. FDA's wording leaves no room: no compounded drug carries its approval, and none is reviewed for safety, effectiveness or quality before it reaches the market.[1]
Read the second half of that sentence as carefully as the first. Not reviewed is not the same as reviewed and found wanting. Compounding is an ordinary and long-standing part of American pharmacy, and FDA's own explanation of why it exists is unglamorous: a patient allergic to a dye, a child who cannot swallow a tablet, a formulation an approved product is not made in.[2] Compounding itself is legitimate. What matters is whether the vial you were sold is one of those cases or a cheaper copy of a product that already exists.
Not every compounder is held to the same standard
This is the distinction that decides most of what follows, and almost no seller explains it. Two entirely different kinds of business make compounded drugs in the United States, under two sections of federal law, and only one of them is inspected by FDA against manufacturing rules.
| 503A pharmacy | 503B outsourcing facility | |
|---|---|---|
| Who licenses it | A state board of pharmacy, which has primary day-to-day oversight.[2] | It registers with FDA, and FDA is its primary overseer.[2] |
| Manufacturing rules | Not subject to current good manufacturing practice requirements.[2] | Must comply with CGMP requirements.[3] |
| Inspection | FDA conducts surveillance and for-cause inspections; routine oversight is the state's.[2] | Inspected by FDA on a risk-based schedule.[3] |
| Adverse event reporting | Federal law does not require it to send adverse events to FDA.[1] | Required to report adverse events, among other conditions.[3] |
| Who it may compound for | An individual patient, on receipt of a prescription for that patient.[4] | May compound without a patient-specific prescription, within the bulks-list and shortage conditions.[4] |
Neither column is the safe one. A 503B facility is inspected against manufacturing standards, and that counts for something. Yet FDA's own register of them listed 98 facilities when we pulled it on August 14, 2026, and 40 of those carried “Not yet inspected”.[8] A 503A pharmacy that has compounded for one prescriber for twenty years may be scrupulous. What the two columns give you is different questions, and the first one to put to any seller is which of the two made your vial (how to tell 503A from 503B). Our register of the pharmacies behind compounded GLP-1 programs is where we track that answer where we can get it, and note where we could not.
What FDA has reported going wrong
The agency keeps a public page of its concerns with unapproved GLP-1 drugs, and it is specific in a way that seller marketing is not. These are the items on it that touch tirzepatide.[1]
Dosing errors, from people measuring their own doses
FDA reports multiple adverse events, some requiring hospitalization, that may relate to dosing errors with compounded injectable semaglutide. The mechanism it describes is arithmetic: patients measuring and self-administering incorrect doses, and in some cases health care professionals miscalculating them.[1] Separately, the agency reports adverse events that may relate to patients being prescribed compounded semaglutide or tirzepatide at doses beyond what the approved label carries (more in a single dose, doses more often, or escalation faster than the label schedule). Some of those were serious. The symptoms that sent people to seek medical attention were the gastrointestinal ones: nausea, vomiting, loose stools, stomach pain, constipation.[1]
The reason this risk attaches to compounded product specifically is concentration. An approved tirzepatide vial states its strength per milliliter on a label FDA reviewed. The multi-dose Zepbound presentations run from 4.17 mg/mL up to 25 mg/mL, four doses per vial, each printed in the prescribing information.[9] A compounded vial's concentration is whatever the compounding pharmacy chose, and it is not on any approved label anywhere. Two vials both labeled tirzepatide can require different volumes for the same milligram dose, which makes the error an easy one to make.
Labels naming pharmacies that do not exist
FDA says it is aware of fraudulent compounded semaglutide and tirzepatide carrying false information on the label. In some cases the pharmacy named on the label does not exist; in others the label names a real licensed pharmacy that, on the information FDA gathered, did not make the product. The agency reports one adverse event tied to a product labeled as compounded tirzepatide from a pharmacy that had not compounded it, with redness, swelling, pain and a red lump at the injection site.[1] A pharmacy name on a label is a claim, not a credential, and it is checkable.
Product arriving warm
Injectable GLP-1 drugs need refrigeration, and FDA has received complaints that compounded ones arrived warm or with too little ice to hold temperature. Its advice is not to use an injectable GLP-1 that turns up that way.[1] This one is easy to check yourself, on the doorstep, and it costs nothing.
Vials sold outside the pharmacy system entirely
FDA has warned companies over unapproved semaglutide, tirzepatide, retatrutide, survodutide and mazdutide carrying one of two false labels: “for research purposes”, or else “not for human consumption”. The agency says those products went straight to consumers, for human use, with dosing instructions attached.[1] These are not a discount version of the pharmacy route. There is no pharmacy, no prescription and no license to look up. We treat them separately in what “research use only” actually means. FDA also says it is aware of counterfeit Ozempic in the U.S. market, and it has issued warning letters to stop illegal online sales of semaglutide and tirzepatide.[1] When we counted our own copy of that letter register on September 27, 2026, 109 of its 149 letters named tirzepatide; the register is browsable on our FDA warning letter register.
Salt forms, and where the record stops
According to FDA, part of the semaglutide compounders sell may be a salt form. The agency names semaglutide sodium and semaglutide acetate, and says these salts are a different active ingredient than the approved drugs contain. It adds that it has no information on whether the salts share the chemical and pharmacologic properties of the approved active ingredient, and that it knows of no lawful basis for compounding with them.[1]
That paragraph is about semaglutide. FDA names no tirzepatide salt on it, and we found no FDA page that names one. The nearest the agency comes for tirzepatide is a grouped sentence in its September 5, 2025 announcement of the import green list, which lists “use of unapproved salt forms” among serious concerns it had previously identified with compounded versions of semaglutide and tirzepatide.[6] So the principle is stated by FDA and the specific named salts are not. If a seller tells you the salt question does not apply to tirzepatide, that is a claim neither of us can check, so ask which substance the pharmacy bought and from whom.
The legal basis closed, which changes who is still selling
Large-scale tirzepatide compounding was lawful mainly because the drug sat on FDA's shortage list. FDA first determined that shortage resolved on October 2, 2024. Litigation sent the decision back to the agency on October 22, 2024, and on December 19, 2024 FDA issued a new determination that the tirzepatide injection shortage was resolved, allowing 503A pharmacies until February 18, 2025 and outsourcing facilities until March 19, 2025.[4] A district court denied the compounders' preliminary injunction on March 5, 2025, and the 503A period ended.[4] As of the agency's April 1, 2026 update, tirzepatide appears on neither the 503B bulks list nor the shortage list, and on April 30, 2026 FDA proposed excluding it from that bulks list outright, finding no clinical need.[4][5] The comment period was extended once and closed on July 30, 2026.[10] As of mid-October 2026 FDA had published no final decision, so the exclusion is still a proposal. The full sequence is in our explanation of which GLP-1s can still be compounded.
The safety consequence is indirect and easy to miss. When a legal basis closes, the operators who cared about it stop, and the ones still shipping at volume are by definition the ones who did not. Compounding for a real individual need remains lawful and narrow. A subscription that ships the same formulation to everyone who fills in the same form is not that, and a seller who cannot say on what basis they are still compounding tirzepatide has answered the question.
What nobody can tell you, because it has not been studied
There is no trial of compounded tirzepatide, not even a small or poorly run one. The efficacy and safety evidence people cite for tirzepatide comes from trials of the approved product, and it does not transfer to a preparation with a different concentration, different excipients and, in some cases, a different route (how such a vial differs from the brand is set out in compounded tirzepatide vs Zepbound).
The closest thing to a survey of what is being sold was published in 2026 in Annals of Pharmacotherapy. Pharmacy researchers searched compounder websites in February and March 2025 and cataloged 33 distinct products; one-third of them contained tirzepatide. Their most useful finding is on documentation: only 18 percent of the products they included published a beyond-use date and preferred storage conditions.[7] MEDLINE indexes that paper as an editorial, so it is a structured look at a market with the authors' judgment attached, not a measurement of anything in a patient. Nothing stronger has been published.
- No published trial tests a compounded tirzepatide formulation against the approved product, or against anything else.
- No published dataset characterizes what an added excipient does in an injectable tirzepatide preparation.
- No comparative harm rate can be computed, because 503A reporting to FDA is not required.[1]
Five questions that get you a real answer
- Which pharmacy made this, 503A or 503B, and what is its license number? A seller who will not name the compounder is telling you something. A named 503B facility can be looked up on FDA's own register.[8]
- On what legal basis is it being compounded now? Tirzepatide is not on the shortage list and not on the 503B bulks list.[4] The answer should be about an individual clinical need, and it should be a real sentence.
- What is the concentration in milligrams per milliliter, and how many units is my dose? Ask in the units printed on the syringe you were sent. This is exactly the arithmetic behind the reported dosing errors.[1]
- What else is in the vial besides tirzepatide? Added ingredients are common in this market,[7] and what they do in an injectable GLP-1 is not characterized. Our look at the B12 in compounded semaglutide works through the same question on the other molecule.
- Who do I call at 9pm if something is wrong? If the answer is a chat widget rather than a clinician, the accountability gap is the product you bought.
Sellers answer the first question very differently. Idgie Health names the Houston compounding pharmacy that fills its orders, and KIN Health names its pharmacy partners. AHBARx sits at the other end: its Terms of Service still carry unfilled template placeholders where the pharmacy name should be. At Pillar Health, checkout runs on a separate platform whose own terms govern billing and refunds, so read those before you pay.
HealthClinic MD, a Pittsburgh telehealth practice, names no pharmacy, and its prices appear in the patient portal only after a provider approves treatment. Nimbus Healthcare, founded by a compounding pharmacist, fills its semaglutide and tirzepatide at a pharmacy it owns and mixes both with L-carnitine, with no plain version offered.
The route question matters too, because the trial record covers the approved injection. Compounded tirzepatide is also sold as an oral lozenge by Strut Health, as a tablet by Chia and as a daily tablet by Vital Step. Idgie Health’s dissolving tablet adds the anti-nausea medicine ondansetron, which is one more answer to “what else is in it.” Prime Doctor RX, Science & Co and Trally Meds sell it as an injection, and Trally Meds lists phone support; for the last question, ask which hours it covers and whether a clinician answers.
If you are weighing this against the approved product, compare current figures rather than ones you saw a year ago. We keep dated figures for every seller we track on the price tracker, and our ranked board for compounded tirzepatide records what each program will and will not tell you about its pharmacy.
Brand prices are not uniform either. Elara Women’s Wellness lists brand-name Wegovy and Zepbound at $1,400 to $1,697 a month, far above the makers’ own self-pay prices.
Frequently Asked Questions
References
- 1.U.S. Food and Drug Administration FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss FDA Drug Alerts and Statements. 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- 2.U.S. Food and Drug Administration Compounding and the FDA: Questions and Answers FDA Human Drug Compounding. 2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- 3.U.S. Food and Drug Administration Information for Outsourcing Facilities FDA Human Drug Compounding. 2026. https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities
- 4.U.S. Food and Drug Administration FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize FDA Drug Alerts and Statements. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- 5.U.S. Food and Drug Administration FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List FDA Press Announcements. 2026. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- 6.U.S. Food and Drug Administration FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients FDA Press Announcements. 2025. https://www.fda.gov/news-events/press-announcements/fda-launches-green-list-protect-americans-illegal-imported-glp-1-drug-ingredients
- 7.Belcourt J, Sapowadia A, White CM. Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown. Ann Pharmacother 2026;60(9):902-906 (editorial). 2026. PMID: 41689811.
- 8.U.S. Food and Drug Administration Registered Outsourcing Facilities FDA Human Drug Compounding. 2026. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- 9.Eli Lilly and Company ZEPBOUND (tirzepatide) injection, for subcutaneous use — prescribing information, section 3 Dosage Forms and Strengths DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- 10.U.S. Food and Drug Administration List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period Federal Register 91 FR 38719 (FR Doc. 2026-12937). 2026. https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
Compare the sellers
Related research
GLP-1 Eye Risks: Diabetic Retinopathy and NAION Are Not the Same Thing
Two distinct eye questions get merged into one headline. Diabetic retinopathy complications are on the semaglutide label and trace to blood sugar falling fast; NAION is a separate optic-nerve signal that Europe's drug-safety committee recommended adding to product information in June 2025, and US labeling still does not mention.
12 min read
GLP-1 Thyroid Cancer Risk: What the Boxed Warning Actually Says
A boxed warning about thyroid C-cell tumors sits on every semaglutide and tirzepatide label there is. It comes from rodent studies, the labels themselves say the human relevance is undetermined, and the human research published since does not agree with itself.
11 min read
How Much Does Compounded Semaglutide Cost? What Drives the Number
Compounded GLP-1 prices are quoted in ways that hide what you will be charged. This is the structure of the bill, and where on this site the dated numbers live.
9 min read
Compounded Semaglutide and Tirzepatide Are Ending: What to Do Next
The federal permission that made large-scale GLP-1 compounding lawful has closed. Three routes remain, one to avoid, and the questions to ask before you move.
6 min read
Compounded Semaglutide: Is a Prescription Required?
Yes, but 503A and 503B do not carry the same requirement, and the gap between them is where the no-prescription pitches live. What each route actually asks for.
5 min read
503A vs 503B Compounding Pharmacies: Who Oversees Your Compounded GLP-1
A 503A pharmacy compounds per patient under a state board. A 503B outsourcing facility registers with FDA, follows CGMP, is inspected and must report adverse events. What each means for compounded GLP-1s, and how to check yours.
10 min read
Where to get tirzepatide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
bmiMD
Starting below a standard dose, with microdose tiers
From $179/mo, prepaid
Get started →WellMedRx
Comparing compounded and brand GLP-1 plans with a published state list
From $89/mo
Get started →Direct Meds
From $299/mo
Get started →